Financial Survey: Cortexyme (NASDAQ:CRTX) vs. Finch Therapeutics Group (NASDAQ:FNCH)

Earnings and Valuation

This table compares Cortexyme and Finch Therapeutics Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.53
Finch Therapeutics Group	N/A	N/A	-$74.75 million	($8.82)	-1.66

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cortexyme and Finch Therapeutics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-70.96%	-63.53%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Risk & Volatility

Cortexyme has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Insider & Institutional Ownership

63.2% of Cortexyme shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 27.9% of Cortexyme shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.